EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, Miguel Servet University Hospital, 50009, Zaragoza, Spain.
Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), ISCIII, 28029, Madrid, Spain.
Sci Rep. 2024 Oct 3;14(1):22977. doi: 10.1038/s41598-024-73032-4.
Male breast cancer (MBC) is a rare condition with unique characteristics compared to female breast cancer (FBC). Despite its scarceness, there is growing evidence that MBC should not be studied and treated as FBC due to factors like later diagnosis stage and distinct genetic makeup. Retrospective observational study in the EpiChron Cohort, selecting all the prevalent patients with breast cancer between 2010 and 2019. Logistic models were used to determine associated comorbidities. Between 2010 and 2019, 105 MBC and 11,657 FBC patients were found in the EpiChron Cohort. MBC patients had a high mean age at diagnosis and number of comorbidities. Paying attention to comorbidity prevalences in breast cancer patients, it was clear that MBC patients tended to be prone to cardio-metabolic coexisting diseases, while FBC patients were more prone to hormone-, bone- and mental diseases. There were nine chronic conditions associated to MBC patients, but after a year-by-birth matching only four associations remained. Two of them were associated previously [odds ratio (95% confidence interval)]: "Disorder of lipid metabolism" [1.65 (1.03-2.64)] and "Genitourinary symptoms and ill-defined conditions" [2.03 (1.07-3.87)]; and the other two were new, "Anxiety disorders" [2.05 (1.09-3.87)] and "Osteoporosis" [3.58 (1.26-10.14)]. After comparing associated comorbidities in FBC with those in MBC, it seems MBC patients share some of them, but they have their own particular set of coexisting diseases. In fact, once a year-by-birth matching was performed in MBC patient cohort, it was more obvious MBC comorbidities behave more similar to none-Breast-Cancer male population than to FBC patients. These findings highlight the distinct characteristics of the MBC patient population and the need for a tailored approach of managing MBC.
男性乳腺癌（MBC）是一种罕见的疾病，与女性乳腺癌（FBC）相比具有独特的特征。尽管其发病率较低，但越来越多的证据表明，由于诊断阶段较晚和独特的遗传构成等因素，MBC 不应被视为 FBC 进行研究和治疗。在 EpiChron 队列中进行回顾性观察性研究，该研究选择了 2010 年至 2019 年间所有患有乳腺癌的现患患者。使用逻辑模型确定相关合并症。在 2010 年至 2019 年间，EpiChron 队列中发现了 105 例 MBC 和 11657 例 FBC 患者。MBC 患者的诊断时平均年龄较高，合并症数量较多。关注乳腺癌患者的合并症患病率，很明显，MBC 患者更容易患心血管代谢并存疾病，而 FBC 患者更容易患激素、骨骼和精神疾病。有九种慢性疾病与 MBC 患者相关，但经过逐年后匹配后，只有四种关联仍然存在。其中两种先前有相关性[比值比（95%置信区间）]：“脂质代谢紊乱”[1.65（1.03-2.64）]和“泌尿生殖系统症状和定义不明确的疾病”[2.03（1.07-3.87）]；另外两种是新的，“焦虑障碍”[2.05（1.09-3.87）]和“骨质疏松症”[3.58（1.26-10.14）]。比较 FBC 和 MBC 患者的相关合并症后，似乎 MBC 患者有一些共同的合并症，但也有自己独特的一组并存疾病。事实上，在对 MBC 患者队列进行逐年后匹配后，更明显的是，MBC 合并症的表现更类似于非乳腺癌男性人群，而不是 FBC 患者。这些发现突出了 MBC 患者人群的独特特征，需要采取有针对性的方法来管理 MBC。
